New York, January 30, 2015 -- Moody's Investors Service commented that the expansion in the oncology market by Valeant Pharmaceuticals International, Inc. ("Valeant") is credit positive but has execution risk. There is currently no impact on Valeant's ratings including the Ba3 Corporate Family Rating, Ba1 senior secured rating and B1 senior unsecured rating.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.